Norvir

(Ritonavir)

ApprovedSmall molecule

Ritonavir is used to treat HIV infection by slowing the virus's ability to multiply in the body. It's often combined with other HIV medications to help keep the infection under control.[2] Norvir is currently approved and in use across 35 indications[4].[1]

Norvir is one of 826 small molecule programs targeting Glioma. It is currently in Approved.

Indications

318

Total Trials

Active Trials

825

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

AIDSApproved

Anal NeoplasmApproved

Middle East Respiratory SyndromeApproved

HIV InfectionActive, not recruiting

MetastasisApproved

Viral DiseaseActive, not recruiting

Erectile DysfunctionApproved

ToxicityActive, not recruiting

HepatitisActive, not recruiting

GliomaPhase 1

Active, not recruiting

AIDSApproved

Approved

Anal NeoplasmApproved

Approved

Middle East Respiratory SyndromeApproved

Approved

HIV InfectionApproved

Active, not recruiting

MetastasisApproved

Approved

Viral DiseaseApproved

Active, not recruiting

Erectile DysfunctionApproved

Approved

ToxicityApproved

Active, not recruiting

HepatitisPhase 2

Active, not recruiting

Showing 10 of 35 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Norvir

AbbVie

Approved

1 2

Trodelvy

Gilead

Preclinical

37 3

Halaven

Eisai

Preclinical

38 4

Megace

Bristol-Myers Squibb

Preclinical

4 5

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 6

Zolymbus

AbbVie

Preclinical

1 7

Blenoxane

Bristol-Myers Squibb

Preclinical

1 8

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 10

Chirocaine

PPurdue Pharma LP

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

COVID-19

NCT05261139

Phase 1Recruiting

Advanced Breast Cancer

NCT06710990

Clinical

Trials by Indication[1]

Interaction22 trials

The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT01896622·40 enrolled

Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of Ritonavir

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253836·21 enrolled

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin

Completed·UUniversity of Colorado, Denver·Phase 4·NCT00630734·32 enrolled

Show 19 more trials

A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01588002·40 enrolled

A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01531647·20 enrolled

A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01519336·40 enrolled

A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs

Completed·RR-Pharm·Phase 1·NCT03537404·36 enrolled

Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir in Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02256774·51 enrolled

A Study on the Interaction Between Danoprevir/Ritonavir and Methadone

Completed· Roche logo

Roche·Phase 1·NCT01389544·18 enrolled

The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02251119·24 enrolled

A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01514968·18 enrolled

Pharmacokinetic Interaction Between Ritonavir and Prasugrel in Healthy Volunteers

Completed·UUniversity Hospital, Geneva·Phase 1·NCT01346800·10 enrolled

A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000941·56 enrolled

GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir

Completed· GSK logo

GSK·Phase 1·NCT00867152·17 enrolled

A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat

Completed·RRadboud University Medical Center·Phase 1·NCT02565888·16 enrolled

Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02256826·34 enrolled

A Study of Drug-drug Interaction Between Ritonavir and TMC435350 in Healthy Volunteers

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 1·NCT01891851·12 enrolled

Drug-Drug Interaction Between Colchicine and Ritonavir

Completed·MMutual Pharmaceutical Company, Inc.·Phase 1·NCT00983515·24 enrolled

Drug Interaction Between Ritonavir And Sitaxsentan

Withdrawn· Pfizer logo

Pfizer·Phase 1·NCT01251848

Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00039975·32 enrolled

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

Completed· GSK logo

GSK·Phase 1·NCT01209065·27 enrolled

The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000898·18 enrolled

Treatment13 trials

A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients

Completed· Roche logo

Roche·Phase 3·NCT00002178·375 enrolled

Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1

Completed·NNorthwestern University·Phase 2·NCT00993148·25 enrolled

A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients

Completed· Roche logo

Roche·Phase 1·NCT01638650·23 enrolled

Show 10 more trials

Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment

Active, not recruiting·NNova Scotia Health Authority·Phase 4·NCT02460133·44 enrolled

Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment

Completed·TTibotec, Inc·Phase 4·NCT00757783·68 enrolled

Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00012519·29 enrolled

Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00158405·840 enrolled

TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00896051·50 enrolled

Atazanavir and Lamivudine for Treatment Simplification

Completed·—·Phase 4·NCT00885482·40 enrolled

Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT02249130·18 enrolled

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

Terminated· GSK logo

GSK·Phase 2·NCT02386098·86 enrolled

A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00006152·42 enrolled

A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients

Completed·TTibotec, Inc·Phase 2·NCT01199939·54 enrolled

Tics11 trials

Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02251769·24 enrolled

A Study to Evaluate the Effect of Danoprevir/Ritonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01418274·20 enrolled

Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

Completed·AAscletis Pharmaceuticals Co., Ltd.·Phase 1·NCT03288636·18 enrolled

Show 8 more trials

Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China

Completed·AAscletis Pharmaceuticals Co., Ltd.·Phase 1·NCT03020134·18 enrolled

Pharmacokinetics and Safety of BILR 355 in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253940·40 enrolled

Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of BILR 355 BS Plus Low Dose Ritonavir in HIV-uninfected Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253914·100 enrolled

The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT01148004·25 enrolled

Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02159352·49 enrolled

Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China

Completed·AAscletis Pharmaceuticals Co., Ltd.·Phase 1·NCT03019991·18 enrolled

A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT01810887·8 enrolled

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02064842·24 enrolled

Chronic Hepatitis8 trials

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

Completed· Roche logo

Roche·Phase 2·NCT01278134·170 enrolled

Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)

Completed·RR-Pharm·Phase 3·NCT03833362·420 enrolled

A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

Completed· Roche logo

Roche·Phase 2·NCT01483742·43 enrolled

Show 5 more trials

A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

Completed· Roche logo

Roche·Phase 1·NCT01185860·59 enrolled

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

Completed·RR-Pharm·Phase 2·NCT04246723·85 enrolled

Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01852604·143 enrolled

A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)

Completed· AbbVie logo

AbbVie·Phase 2·NCT01458535·61 enrolled

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment

Withdrawn· Roche logo

Roche·Phase 2·NCT01579019

Effectiveness8 trials

Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir

Terminated·AAgouron Pharmaceuticals·N/A·NCT00006326·60 enrolled

Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Unknown status· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002451·8 enrolled

Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment

Unknown status· GSK logo

GSK·Phase 4·NCT00005017·300 enrolled

Show 5 more trials

A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000914·800 enrolled

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 3·NCT00524368·590 enrolled

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001075·55 enrolled

Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00004584

Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002361·30 enrolled

68 more indications

Drug7 trials

A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

Completed· GSK logo

GSK·Phase 1·NCT03234036·26 enrolled

Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs

Unknown status· GSK logo

GSK·Phase 3·NCT00009061·624 enrolled

A Study to Compare Two Anti-HIV Drug Combinations

Completed· Roche logo

Roche·Phase 3·NCT00002447·146 enrolled

Show 4 more trials

A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000892·300 enrolled

A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 2·NCT00002440·80 enrolled

A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04055506·16 enrolled

Once-Daily Drug Regimen for HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001968·25 enrolled

Adult7 trials

Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450

Completed·AAbbott·Phase 1·NCT01091649·40 enrolled

Effects of TPV/r on the Pharmacokinetics of Carbamazepine in Healthy Adult Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253849·28 enrolled

Study to Determine the Effects of Multiple-dose Omeprazole on the Single-dose Pharmacokinetics of Tipranavir (TPV) Coadministered With Ritonavir (RTV) in Healthy Adult Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253875·15 enrolled

Show 4 more trials

A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

Completed· Roche logo

Roche·Phase 2·NCT00002239·68 enrolled

Effects of Single-dose and Steady-state TPV/RTV on the Steady-state Pharmacokinetics of Fluconazole in Healthy Adult Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02195466·20 enrolled

Effects of Steady-state TPV/RTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02251171·24 enrolled

Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

Completed·AAbbott·Phase 1·NCT00931281·38 enrolled

Immunodeficiency6 trials

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02275780·769 enrolled

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Completed· Gilead logo

Gilead·Phase 3·NCT01106586·708 enrolled

A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 2·NCT00355524·80 enrolled

Show 3 more trials

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

Completed· GSK logo

GSK·Phase 2·NCT01384734·254 enrolled

A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 2·NCT00838162·33 enrolled

Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT00552240·154 enrolled

HIV6 trials

Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00028366·56 enrolled

Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT00531206·65 enrolled

Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT02238314·41 enrolled

Show 3 more trials

Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00063804·44 enrolled

Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure

Unknown status· GSK logo

GSK·Phase 3·NCT00025727·330 enrolled

Study to Evaluate the Influence of Nevirapine to Atazanavir in Steady State Equilibrium in HIV Patients

Completed·GGermans Trias i Pujol Hospital·Phase 4·NCT00355719·14 enrolled

HIV-15 trials

A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients

Completed· Roche logo

Roche·Phase 3·NCT00002374·120 enrolled

Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1

Completed· GSK logo

GSK·Phase 2·NCT01009814·50 enrolled

A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects

Completed· GSK logo

GSK·Phase 3·NCT00296504·753 enrolled

Show 2 more trials

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT01332227·132 enrolled

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

Completed·RRockefeller University·N/A·NCT00525733·40 enrolled

Children5 trials

A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.

Completed· Roche logo

Roche·Phase 2·NCT00623597·18 enrolled

A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000952·60 enrolled

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00260078·75 enrolled

Show 2 more trials

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 2·NCT00919854·27 enrolled

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001083·240 enrolled

COVID-194 trials

A Study of Combination Therapies to Treat COVID-19 Infection

Withdrawn·PProgenaBiome·Phase 2·NCT04459702

EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

Completed· Pfizer logo

Pfizer·Phase 2/3·NCT04960202·2,091 enrolled

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT05261139·160 enrolled

Show 1 more trial

A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

Completed· Pfizer logo

Pfizer·Phase 2/3·NCT05047601·2,954 enrolled

Adolescent4 trials

TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01281813·145 enrolled

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 2·NCT00915655·12 enrolled

Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00006604·195 enrolled

Show 1 more trial

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

Completed·IInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group··NCT00977756·168 enrolled

HIV infection3 trials

A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.

Completed· Roche logo

Roche·Phase 1·NCT00435929·16 enrolled

Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT01232127·25 enrolled

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

Completed· GSK logo

GSK·Phase 2·NCT00089583·110 enrolled

Efficacy and Safety3 trials

Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan

Completed·AAscletis Pharmaceuticals Co., Ltd.·Phase 2·NCT03020095·38 enrolled

Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00421551·225 enrolled

Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected Patients

Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00122577·50 enrolled

Drug Resistance3 trials

Efficacy and Tolerability of an Antiretroviral Bi-Therapy in HIV Infected Patients With Multidrug Resistance

Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00120783·40 enrolled

Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00027339·53 enrolled

Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00046033·118 enrolled

Adult Subject3 trials

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

Completed·GGarden State Infectious Disease Associates, PA·Phase 2·NCT00764465·45 enrolled

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

Completed·GGarden State Infectious Disease Associates, PA·N/A·NCT00802074·45 enrolled

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

Completed·GGarden State Infectious Disease Associates, PA·N/A·NCT00614991·44 enrolled

ART3 trials

Comparative Study of Three NNRTI-Sparing HAART Regimens

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 3·NCT00811954·1,814 enrolled

Food Effects of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants

Unknown status·FFujian Akeylink Biotechnology Co., Ltd.·Phase 1·NCT06084507·18 enrolled

SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

Unknown status·CClinical Alliance for Research & Education - Infectious Diseases, LLC.·Phase 4·NCT00426296

Randomized3 trials

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00440271·33 enrolled

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

Completed· AbbVie logo

AbbVie·Phase 2·NCT01074008·74 enrolled

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00054717·630 enrolled

TED2 trials

Single and Repeated Dose Escalation Study of GSK2838232

Completed· GSK logo

GSK·Phase 1·NCT02795754·62 enrolled

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

Completed· Gilead logo

Gilead·Phase 4·NCT00224445·100 enrolled

Combination Therapy2 trials

A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT01391013·30 enrolled

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01448707·274 enrolled

Single Dose2 trials

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Terminated· GSK logo

GSK·Phase 1·NCT02289482·20 enrolled

Dose Escalation Study of Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BILR 355 (SDS) Plus Low-dose Ritonavir in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253927·48 enrolled

MPR2 trials

Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir

Completed·RRadboud University Medical Center·Phase 1·NCT00817765·24 enrolled

Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00196625·100 enrolled

Tenofovir Disoproxil Fumarate2 trials

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 3·NCT00118898·1,864 enrolled

A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir

Completed· Roche logo

Roche·Phase 1·NCT01592305·40 enrolled

HIV-1 infection2 trials

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

Approved for marketing· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT00097799

A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT00976950·42 enrolled

Drug Interactions2 trials

Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00005762·90 enrolled

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00833482·185 enrolled

Concentration2 trials

Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02226991·34 enrolled

Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1/2·NCT02229760·3 enrolled

Women2 trials

Differences Between Women and Men Taking a Combination of Indinavir, Ritonavir, Enteric-Coated Didanosine, and Stavudine Who Previously Took Anti-HIV Drugs

Unknown status·PPPD Development, LP·Phase 3·NCT00006397·200 enrolled

A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women

Completed· Pfizer logo

Pfizer·Phase 1·NCT05441215·8 enrolled

Female2 trials

Bioequivalence Study of Tipranavir Stored at Controlled Temperature Compared With Tipranavir Stored at Controlled Refrigerated Conditions, Orally Co-administered With Ritonavir in Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253888·30 enrolled

Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02251158·30 enrolled

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT03383692·40 enrolled

Pregnancy1 trial

Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000920·24 enrolled

Pilot Study1 trial

A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001688·25 enrolled

Advanced Breast Cancer1 trial

Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer

Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT06710990·32 enrolled

Prostate Cancer1 trial

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

Terminated·UUniversity of Chicago·Phase 1·NCT05679388·60 enrolled

Lymphoma1 trial

Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma

Withdrawn·MMayo Clinic·N/A·NCT01165645

Immune System1 trial

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001119·288 enrolled

Second-line Treatment1 trial

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01605084

Intravenous1 trial

A Pharmacokinetic And Bioavailability Study of Intravenous Danoprevir in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01654211·33 enrolled

Pregnant Women1 trial

A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00855335·77 enrolled

Viremia1 trial

HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 4·NCT00855413·15 enrolled

Hepatitis C1 trial

Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1

Completed· AbbVie logo

AbbVie·Phase 1·NCT00850044·87 enrolled

Pediatric Patients1 trial

Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01335698·160 enrolled

Imaging1 trial

LAAM-HAART PET Imaging

Completed·WWashington University School of Medicine·Phase 1·NCT01935830·10 enrolled

Impaired Renal Function1 trial

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT02116660·11 enrolled

Hepatitis D Virus Infection1 trial

Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection

Unknown status·SSoroka University Medical Center·Phase 3·NCT05229991·30 enrolled

CLE1 trial

Nucleosides And Darunavir/Dolutegravir In Africa

Unknown status·MMakerere University·Phase 3·NCT03988452·465 enrolled

Pediatric1 trial

A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years

Completed· GSK logo

GSK·Phase 2·NCT00040664·69 enrolled

Mycobacterium Avium Complex1 trial

A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001058·246 enrolled

HIV-Infected Individuals1 trial

A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000822·46 enrolled

Cardiovascular1 trial

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections··NCT00851799·334 enrolled

Function1 trial

Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function

Completed· GSK logo

GSK·Phase 4·NCT00717067·30 enrolled

ISS1 trial

Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT00855088·13 enrolled

Observational Study1 trial

An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT01615601·77 enrolled

Resistance1 trial

Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00517192·40 enrolled

Moderate Hepatic Insufficiency1 trial

Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02249442·24 enrolled

Trial1 trial

Body Composition Sub-study of the D2EFT Trial

Completed·KKirby Institute·Phase 4·NCT03675815·155 enrolled

AIN1 trial

Efavirenz and Ritonavir on Human Brain P-Glycoprotein

Completed·WWashington University School of Medicine·Phase 1/2·NCT01668147·13 enrolled

Chronic Hepatitis C Virus Infection1 trial

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

Completed· Roche logo

Roche·Phase 2·NCT01220947·421 enrolled

Long COVID1 trial

Paxlovid for Treatment of Long Covid

Completed·SStanford University·Phase 2·NCT05576662·168 enrolled

Fed1 trial

TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted Conditions

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 1·NCT01308658·128 enrolled

HBV1 trial

Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00447902·11 enrolled

Oral1 trial

Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02244190·32 enrolled

Kaposi's sarcoma1 trial

The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma

Completed·AAbbott·Phase 2·NCT00002366

Radiation Therapy1 trial

External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases

Unknown status·OOncology Institute of Southern Switzerland·Phase 2·NCT00637637·60 enrolled

Drug Therapy1 trial

A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000902·217 enrolled

Hepatitis1 trial

Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT02511431·22 enrolled

Statin1 trial

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz

Completed·NNYU Langone Health·Phase 1·NCT01695954·34 enrolled

Toxicity1 trial

NNRTI/PI Toxicity Switch to Darunavir Study

Terminated·SSt Stephens Aids Trust·Phase 4·NCT00765154·12 enrolled

Tenofovir1 trial

Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population

Completed·UUniversity of North Carolina, Chapel Hill··NCT01180075·85 enrolled

Advanced1 trial

Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000891·34 enrolled

Unspecified13 trials

Titrating-Dose of Lonafarnib in Combination With Ritonavir

Completed·EEiger BioPharmaceuticals·Phase 2·NCT02527707·15 enrolled

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

Completed· GSK logo

GSK·Phase 3·NCT00085943·866 enrolled

Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253862·17 enrolled

Show 10 more trials

A Study of Lonafarnib With or Without Ritonavir in Patients With HDV

Withdrawn·EEiger BioPharmaceuticals·Phase 2·NCT02968641

Study of PBI-0451 in Healthy Subjects.

Completed·PPardes Biosciences, Inc.·Phase 1·NCT05011812·130 enrolled

Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02243553·34 enrolled

DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)

Completed· GSK logo

GSK·Phase 1·NCT02063360·42 enrolled

PK of Efavirenz & Lopinavir Nano-formulations in Healthy Volunteers

Suspended·SSt Stephens Aids Trust·Phase 1·NCT02631473·50 enrolled

Bioequivalence Study (Preliminary Study) of Ritonavir Versus NORVIR in Healthy Chinese Subjects

Completed·FFirst Affiliated Hospital of Zhejiang University·Phase 1·NCT03214159·12 enrolled

A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers

Completed·PPyramid Biosciences·Phase 1·NCT05692570·21 enrolled

PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01099579·82 enrolled

A Study of RO5190591 (Danoprevir) in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01164488·18 enrolled

Lonafarnib With and Without Ritonavir in HDV (LOWR-1)

Completed·EEiger BioPharmaceuticals·Phase 2·NCT02430181·21 enrolled

Regulatory

FDA Approval Timeline[5]

Mar 1, 1996

NORVIR

NDA NDA020680

Mar 1, 1996

NORVIR

NDA NDA020659

Jun 29, 1999

NORVIR

NDA NDA020945

Feb 10, 2010

NORVIR

NDA NDA022417

Jun 7, 2017

NORVIR

NDA NDA209512

Sources

References

[1]
ClinicalTrials.gov — 318 trial records for Ritonavir. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Norvir drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Ritonavir compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Ritonavir. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA209512). U.S. Food & Drug Administration.
[6]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Cytochrome P450 3a Inhibitor; Human Immunodeficiency Virus Type 1 Protease Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AbbVie

Norvir

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Interaction22 trials

Treatment13 trials

Tics11 trials

Chronic Hepatitis8 trials

Effectiveness8 trials

Drug7 trials

Adult7 trials

Immunodeficiency6 trials

HIV6 trials

HIV-15 trials

Children5 trials

COVID-194 trials

Adolescent4 trials

HIV infection3 trials

Efficacy and Safety3 trials

Drug Resistance3 trials

Adult Subject3 trials

ART3 trials

Randomized3 trials

TED2 trials

Combination Therapy2 trials

Single Dose2 trials

MPR2 trials

Tenofovir Disoproxil Fumarate2 trials

HIV-1 infection2 trials

Drug Interactions2 trials

Concentration2 trials

Women2 trials

Female2 trials

Drug Monitoring1 trial

Tolerance1 trial

Malignant Tumors1 trial

Pregnancy1 trial

Pilot Study1 trial

Advanced Breast Cancer1 trial

Prostate Cancer1 trial

Lymphoma1 trial

Immune System1 trial

Second-line Treatment1 trial

Intravenous1 trial

Pregnant Women1 trial

Viremia1 trial

Hepatitis C1 trial

Pediatric Patients1 trial

Imaging1 trial

Impaired Renal Function1 trial

Hepatitis D Virus Infection1 trial

CLE1 trial

Pediatric1 trial

Mycobacterium Avium Complex1 trial

HIV-Infected Individuals1 trial

Cardiovascular1 trial

Function1 trial

ISS1 trial

Observational Study1 trial

Resistance1 trial

Moderate Hepatic Insufficiency1 trial

Trial1 trial

AIN1 trial

Chronic Hepatitis C Virus Infection1 trial

Long COVID1 trial

Fed1 trial

HBV1 trial

Oral1 trial

Kaposi's sarcoma1 trial

Radiation Therapy1 trial

Drug Therapy1 trial

Hepatitis1 trial

Statin1 trial

Toxicity1 trial

Tenofovir1 trial

Advanced1 trial

Unspecified13 trials

FDA Approval Timeline[5]